<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Patient Health Record</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Allergies</a></li><li><a href="#id2">Results</a></li><li><a href="#id3">Reason For Referral</a></li><li><a href="#id4">Medications</a></li><li><a href="#id5">Immunizations</a></li><li><a href="#id6">Social History</a></li><li><a href="#id7">Problems</a></li><li><a href="#id8">Vital Signs</a></li><li><a href="#id9">Procedures</a></li><li><a href="#id10">Encounters</a></li><li><a href="#id11">Medical Equipment</a></li><li><a href="#id12">Assessments</a></li><li><a href="#id13">Plan Of Treatment</a></li><li><a href="#id14">Goals Section</a></li><li><a href="#id15">Health Concerns</a></li><li><a href="#id16">Insurance Providers</a></li><li><a href="#id17">Medical (General) History</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Allergies</a></h3><div><span class="content_span">No Known Allergies</span></div><h3><a name="id2" href="#toc">Results</a></h3><div><table width="100%" border="1"><thead><tr><th>Component</th><th>Value</th><th>Reference Range</th><th>Notes</th></tr></thead><tbody><tr><td colspan="4"><span class="content_span">Comp. Metabolic Panel (14)-322000</span><br/>Reviewed date:[REDACTED] 12:47:32 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result1_attr1">Glucose</td><td>111</td><td>70-99 mg/dL</td><td/></tr><tr><td ID="result1_attr2">BUN</td><td>14</td><td>8-27 mg/dL</td><td/></tr><tr><td ID="result1_attr3">Creatinine</td><td>1.26</td><td>0.76-1.27 mg/dL</td><td/></tr><tr><td ID="result1_attr4">eGFR</td><td>58</td><td>&gt;59 mL/min/1.73</td><td/></tr><tr><td ID="result1_attr5">BUN/Creatinine Ratio</td><td>11</td><td>10-24</td><td/></tr><tr><td ID="result1_attr6">Sodium</td><td>145</td><td>134-144 mmol/L</td><td/></tr><tr><td ID="result1_attr7">Potassium</td><td>5.2</td><td>3.5-5.2 mmol/L</td><td/></tr><tr><td ID="result1_attr8">Chloride</td><td>107</td><td>96-106 mmol/L</td><td/></tr><tr><td ID="result1_attr9">Carbon Dioxide, Total</td><td>23</td><td>20-29 mmol/L</td><td/></tr><tr><td ID="result1_attr10">Calcium</td><td>9.6</td><td>8.6-10.2 mg/dL</td><td/></tr><tr><td ID="result1_attr11">Protein, Total</td><td>7.3</td><td>6.0-8.5 g/dL</td><td/></tr><tr><td ID="result1_attr12">Albumin</td><td>4.5</td><td>3.8-4.8 g/dL</td><td/></tr><tr><td ID="result1_attr13">Globulin, Total</td><td>2.8</td><td>1.5-4.5 g/dL</td><td/></tr><tr><td ID="result1_attr14">A/G Ratio</td><td>1.6</td><td>1.2-2.2</td><td/></tr><tr><td ID="result1_attr15">Bilirubin, Total</td><td>1.0</td><td>0.0-1.2 mg/dL</td><td/></tr><tr><td ID="result1_attr16">Alkaline Phosphatase</td><td>73</td><td>44-121 IU/L</td><td/></tr><tr><td ID="result1_attr17">AST (SGOT)</td><td>24</td><td>0-40 IU/L</td><td/></tr><tr><td ID="result1_attr18">ALT (SGPT)</td><td>18</td><td>0-44 IU/L</td><td/></tr><tr><td colspan="4"><span class="content_span">CBC With Differential/Platelet-005009</span><br/>Reviewed date:[REDACTED] 12:47:38 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result2_attr1">WBC</td><td>6.3</td><td>3.4-10.8 x10E3/uL</td><td/></tr><tr><td ID="result2_attr2">RBC</td><td>5.70</td><td>4.14-5.80 x10E6/uL</td><td/></tr><tr><td ID="result2_attr3">Hemoglobin</td><td>11.2</td><td>13.0-17.7 g/dL</td><td/></tr><tr><td ID="result2_attr4">Hematocrit</td><td>36.7</td><td>37.5-51.0 %</td><td/></tr><tr><td ID="result2_attr5">MCV</td><td>64</td><td>79-97 fL</td><td/></tr><tr><td ID="result2_attr6">MCH</td><td>19.6</td><td>26.6-33.0 pg</td><td/></tr><tr><td ID="result2_attr7">MCHC</td><td>30.5</td><td>31.5-35.7 g/dL</td><td/></tr><tr><td ID="result2_attr8">RDW</td><td>21.1</td><td>11.6-15.4 %</td><td/></tr><tr><td ID="result2_attr9">Platelets</td><td>214</td><td>150-450 x10E3/uL</td><td/></tr><tr><td ID="result2_attr10">Neutrophils</td><td>66</td><td>Not Estab. %</td><td/></tr><tr><td ID="result2_attr11">Lymphs</td><td>23</td><td>Not Estab. %</td><td/></tr><tr><td ID="result2_attr12">Monocytes</td><td>7</td><td>Not Estab. %</td><td/></tr><tr><td ID="result2_attr13">Eos</td><td>3</td><td>Not Estab. %</td><td/></tr><tr><td ID="result2_attr14">Basos</td><td>1</td><td>Not Estab. %</td><td/></tr><tr><td ID="result2_attr15">Neutrophils (Absolute)</td><td>4.1</td><td>1.4-7.0 x10E3/uL</td><td/></tr><tr><td ID="result2_attr16">Lymphs (Absolute)</td><td>1.5</td><td>0.7-3.1 x10E3/uL</td><td/></tr><tr><td ID="result2_attr17">Monocytes(Absolute)</td><td>0.4</td><td>0.1-0.9 x10E3/uL</td><td/></tr><tr><td ID="result2_attr18">Eos (Absolute)</td><td>0.2</td><td>0.0-0.4 x10E3/uL</td><td/></tr><tr><td ID="result2_attr19">Baso (Absolute)</td><td>0.1</td><td>0.0-0.2 x10E3/uL</td><td/></tr><tr><td ID="result2_attr20">Immature Granulocytes</td><td>0</td><td>Not Estab. %</td><td/></tr><tr><td ID="result2_attr21">Immature Grans (Abs)</td><td>0.0</td><td>0.0-0.1 x10E3/uL</td><td/></tr><tr><td colspan="4"><span class="content_span">Lipid Panel-303756</span><br/>Reviewed date:[REDACTED] 12:47:43 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result3_attr1">Cholesterol, Total</td><td>136</td><td>100-199 mg/dL</td><td/></tr><tr><td ID="result3_attr2">Triglycerides</td><td>128</td><td>0-149 mg/dL</td><td/></tr><tr><td ID="result3_attr3">HDL Cholesterol</td><td>40</td><td>&gt;39 mg/dL</td><td/></tr><tr><td ID="result3_attr4">VLDL Cholesterol Cal</td><td>23</td><td>5-40 mg/dL</td><td/></tr><tr><td ID="result3_attr5">LDL Chol Calc (NIH)</td><td>73</td><td>0-99 mg/dL</td><td/></tr><tr><td colspan="4"><span class="content_span">Litholink CKD Program-910343</span><br/>Reviewed date:[REDACTED] 12:47:47 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result4_attr1">Interpretation</td><td>Note</td><td/><td ID="result4_attr1_notes"><p>EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT</p><p>The overall regression of eGFR with time is not</p><p>statistically significant. Current eGFR is 58 mL/min/1.73mE2</p><p>corresponding to CKD stage 3a. Potassium is within goal and</p><p>has not changed significantly, was 5.0 and now is 5.2</p><p>mmol/L.</p><p>EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS</p><p>-</p><p>Guidelines recommend a target blood pressure of 120/80 mmHg</p><p>or less to reduce cardiovascular risk and CKD progression. A</p><p>higher blood pressure target may be appropriate in older</p><p>individuals to avoid symptomatic hypotension. Assessment of</p><p>albuminuria (urine albumin:creatinine ratio or urine</p><p>protein:creatinine ratio preferred) is recommended at least</p><p>annually in CKD patients for staging and disease prognosis.</p><p>EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP</p><p>-</p><p>fasting Renal Panel [REDACTED]; Spot Urine Panel</p><p>(Albumin preferred) is recommended by guidelines, at least</p><p>yearly;</p><p>BONE and MINERAL ASSESSMENT</p><p>Calcium is within goal and has not changed significantly,</p><p>was 9.6 and now is 9.6 mg/dL. Carbon Dioxide is within goal</p><p>and has not changed significantly, was 24 and now is 23</p><p>mmol/L.</p><p>BONE and MINERAL TREATMENT SUGGESTIONS</p><p>-</p><p>Interpretations require simultaneous measurements of serum</p><p>calcium and phosphorus.</p><p>BONE and MINERAL FOLLOW-UP</p><p>-</p><p>fasting PTH with Renal Panel is recommended by guidelines,</p><p>at least yearly; 25-Hydroxy Vitamin D is due;</p><p>LIPIDS ASSESSMENT</p><p>LDL-C is normal and has decreased, was 105 and now is 73</p><p>mg/dL. Triglyceride is normal and has not changed</p><p>significantly, was 138 and now is 128 mg/dL. Non-HDL</p><p>Cholesterol is optimal and has decreased, was 130 and now is</p><p>96 mg/dL. HDL-C is normal and has not changed significantly,</p><p>was 42 and now is 40 mg/dL.</p><p>LIPIDS TREATMENT SUGGESTIONS</p><p>-</p><p>Therapeutic lifestyle changes are always valuable to</p><p>maintain optimal blood lipid status (diet, exercise, weight</p><p>management). If at least a 50% LDL reduction from baseline</p><p>has not been achieved, begin or increase statin. Consider</p><p>measurement of LDL particle number or Apo B to adjudicate</p><p>need for further LDL lowering therapy. If statin cannot be</p><p>tolerated or increased, alternatives include use of an</p><p>intestinal agent (ezetimibe or bile acid sequestrant) or</p><p>niacin.</p><p>LIPIDS FOLLOW-UP</p><p>-</p><p>fasting Lipid Panel [REDACTED];</p><p>ANEMIA ASSESSMENT</p><p>Hemoglobin is low and has decreased, was 12.1 and now is</p><p>CHRONIC KIDNEY DISEASE:</p><p>-------------------------------</p><p>11.2 g/dL. Hemoglobin target assumes ESA is not in use.</p><p>ANEMIA TREATMENT SUGGESTIONS</p><p>-</p><p>Iron deficiency is a common cause of anemia in CKD.</p><p>Recommend measurement of Ferritin and TSAT.</p><p>ANEMIA FOLLOW-UP</p><p>-</p><p>CBC [REDACTED]; Fe/TIBC (TSAT) and Ferritin with CBC is</p><p>due;</p><p>-------------------------------</p><p>DISCLAIMER</p><p>These assessments and treatment suggestions are provided as</p><p>a convenience in support of the physician-patient</p><p>relationship and are not intended to replace the physician's</p><p>clinical judgment. They are derived from national guidelines</p><p>in addition to other evidence and expert opinion. The</p><p>clinician should consider this information within the</p><p>context of clinical opinion and the individual patient.</p><p>SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney</p><p>Disease Improving Global Outcomes (KDIGO) clinical practice</p><p>guidelines are at http://kdigo.org/home/guidelines/.</p><p>National Kidney Foundation Kidney Disease Outcomes Quality</p><p>Initiative (KDOQI (TM)), with its limitations and</p><p>disclaimers, are at www.kidney.org/professionals/KDOQI. This</p><p>program is intended for patients who have been diagnosed</p><p>with stages 3, 4, or pre-dialysis 5 CKD. It is not intended</p><p>for children, pregnant patients, or transplant patients.</p></td></tr><tr><td ID="result4_attr2">PDF</td><td>.</td><td/><td/></tr><tr><td colspan="4"><span class="content_span">Cardiovascular Report-910385</span><br/>Reviewed date:[REDACTED] 12:47:51 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result5_attr1">Interpretation</td><td>Note</td><td/><td ID="result5_attr1_notes">Supplemental report is available.</td></tr><tr><td ID="result5_attr2">PDF</td><td>Not applicable</td><td/><td/></tr><tr><td colspan="4"><span class="content_span">Urinalysis, Complete-003772</span><br/>Reviewed date:[REDACTED] 12:47:56 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result6_attr1">Specific Gravity</td><td>1.011</td><td>1.005-1.030</td><td/></tr><tr><td ID="result6_attr2">pH</td><td>6.5</td><td>5.0-7.5</td><td/></tr><tr><td ID="result6_attr3">Urine-Color</td><td>Yellow</td><td>Yellow</td><td/></tr><tr><td ID="result6_attr4">Appearance</td><td>Clear</td><td>Clear</td><td/></tr><tr><td ID="result6_attr5">WBC Esterase</td><td>Negative</td><td>Negative</td><td/></tr><tr><td ID="result6_attr6">Protein</td><td>Negative</td><td>Negative/Trace</td><td/></tr><tr><td ID="result6_attr7">Glucose</td><td>Negative</td><td>Negative</td><td/></tr><tr><td ID="result6_attr8">Ketones</td><td>Negative</td><td>Negative</td><td/></tr><tr><td ID="result6_attr9">Occult Blood</td><td>Negative</td><td>Negative</td><td/></tr><tr><td ID="result6_attr10">Bilirubin</td><td>Negative</td><td>Negative</td><td/></tr><tr><td ID="result6_attr11">Urobilinogen,Semi-Qn</td><td>0.2</td><td>0.2-1.0 mg/dL</td><td/></tr><tr><td ID="result6_attr12">Nitrite, Urine</td><td>Negative</td><td>Negative</td><td/></tr><tr><td ID="result6_attr13">Microscopic Examination</td><td>See below:</td><td/><td ID="result6_attr13_notes">Microscopic was indicated and was performed.</td></tr><tr><td ID="result6_attr14">WBC</td><td>None seen</td><td>0 -  5 /hpf</td><td/></tr><tr><td ID="result6_attr15">RBC</td><td>None seen</td><td>0 -  2 /hpf</td><td/></tr><tr><td ID="result6_attr16">Epithelial Cells (non renal)</td><td>None seen</td><td>0 - 10 /hpf</td><td/></tr><tr><td ID="result6_attr17">Casts</td><td>None seen</td><td>None seen /lpf</td><td/></tr><tr><td ID="result6_attr18">Bacteria</td><td>None seen</td><td>None seen/Few</td><td/></tr><tr><td colspan="4"><span class="content_span">CBC With Differential/Platelet-005009</span><br/>Reviewed date:[REDACTED] 05:40:59 PM<br/>Interpretation:Abnormal<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result7_attr1">WBC</td><td>6.5</td><td>3.4-10.8 x10E3/uL</td><td/></tr><tr><td ID="result7_attr2">RBC</td><td>5.83</td><td>4.14-5.80 x10E6/uL</td><td/></tr><tr><td ID="result7_attr3">Hemoglobin</td><td>11.4</td><td>13.0-17.7 g/dL</td><td/></tr><tr><td ID="result7_attr4">Hematocrit</td><td>38.0</td><td>37.5-51.0 %</td><td/></tr><tr><td ID="result7_attr5">MCV</td><td>65</td><td>79-97 fL</td><td/></tr><tr><td ID="result7_attr6">MCH</td><td>19.6</td><td>26.6-33.0 pg</td><td/></tr><tr><td ID="result7_attr7">MCHC</td><td>30.0</td><td>31.5-35.7 g/dL</td><td/></tr><tr><td ID="result7_attr8">RDW</td><td>21.3</td><td>11.6-15.4 %</td><td/></tr><tr><td ID="result7_attr9">Platelets</td><td>185</td><td>150-450 x10E3/uL</td><td/></tr><tr><td ID="result7_attr10">Neutrophils</td><td>63</td><td>Not Estab. %</td><td/></tr><tr><td ID="result7_attr11">Lymphs</td><td>26</td><td>Not Estab. %</td><td/></tr><tr><td ID="result7_attr12">Monocytes</td><td>6</td><td>Not Estab. %</td><td/></tr><tr><td ID="result7_attr13">Eos</td><td>3</td><td>Not Estab. %</td><td/></tr><tr><td ID="result7_attr14">Basos</td><td>1</td><td>Not Estab. %</td><td/></tr><tr><td ID="result7_attr15">Neutrophils (Absolute)</td><td>4.1</td><td>1.4-7.0 x10E3/uL</td><td/></tr><tr><td ID="result7_attr16">Lymphs (Absolute)</td><td>1.7</td><td>0.7-3.1 x10E3/uL</td><td/></tr><tr><td ID="result7_attr17">Monocytes(Absolute)</td><td>0.4</td><td>0.1-0.9 x10E3/uL</td><td/></tr><tr><td ID="result7_attr18">Eos (Absolute)</td><td>0.2</td><td>0.0-0.4 x10E3/uL</td><td/></tr><tr><td ID="result7_attr19">Baso (Absolute)</td><td>0.1</td><td>0.0-0.2 x10E3/uL</td><td/></tr><tr><td ID="result7_attr20">Immature Granulocytes</td><td>1</td><td>Not Estab. %</td><td/></tr><tr><td ID="result7_attr21">Immature Grans (Abs)</td><td>0.0</td><td>0.0-0.1 x10E3/uL</td><td/></tr><tr><td colspan="4"><span class="content_span">Basic Metabolic Panel (7)-303758</span><br/>Reviewed date:[REDACTED] 05:40:59 PM<br/>Interpretation:Abnormal<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result8_attr1">Glucose</td><td>102</td><td>70-99 mg/dL</td><td/></tr><tr><td ID="result8_attr2">BUN</td><td>14</td><td>8-27 mg/dL</td><td/></tr><tr><td ID="result8_attr3">Creatinine</td><td>1.25</td><td>0.76-1.27 mg/dL</td><td/></tr><tr><td ID="result8_attr4">eGFR</td><td>58</td><td>&gt;59 mL/min/1.73</td><td/></tr><tr><td ID="result8_attr5">BUN/Creatinine Ratio</td><td>11</td><td>10-24</td><td/></tr><tr><td ID="result8_attr6">Sodium</td><td>141</td><td>134-144 mmol/L</td><td/></tr><tr><td ID="result8_attr7">Potassium</td><td>5.1</td><td>3.5-5.2 mmol/L</td><td/></tr><tr><td ID="result8_attr8">Chloride</td><td>104</td><td>96-106 mmol/L</td><td/></tr><tr><td ID="result8_attr9">Carbon Dioxide, Total</td><td>26</td><td>20-29 mmol/L</td><td/></tr><tr><td colspan="4"><span class="content_span">Litholink CKD Program-910343</span><br/>Reviewed date:[REDACTED] 05:40:59 PM<br/>Interpretation:<br/>Performing Lab:Labcorp [REDACTED], [REDACTED][REDACTED] Phone - [REDACTED], Director - MDFarrier<br/>Notes/Report:</td></tr><tr><td ID="result9_attr1">Interpretation</td><td>Note</td><td/><td ID="result9_attr1_notes"><p>CHRONIC KIDNEY DISEASE:</p><p>EGFR, BLOOD PRESSURE, AND PROTEINURIA ASSESSMENT</p><p>The overall regression of eGFR with time is not</p><p>statistically significant. Current eGFR is 58 mL/min/1.73mE2</p><p>corresponding to CKD stage 3a. Potassium is within goal and</p><p>has not changed significantly, was 5.2 and now is 5.1</p><p>mmol/L.</p><p>EGFR, BLOOD PRESSURE, AND PROTEINURIA TREATMENT SUGGESTIONS</p><p>-</p><p>Guidelines recommend a target blood pressure of 120/80 mmHg</p><p>or less to reduce cardiovascular risk and CKD progression. A</p><p>higher blood pressure target may be appropriate in older</p><p>individuals to avoid symptomatic hypotension. Assessment of</p><p>albuminuria (urine albumin:creatinine ratio or urine</p><p>protein:creatinine ratio preferred) is recommended at least</p><p>-------------------------------</p><p>annually in CKD patients for staging and disease prognosis.</p><p>EGFR, BLOOD PRESSURE, AND PROTEINURIA FOLLOW-UP</p><p>-</p><p>fasting Renal Panel [REDACTED]; Spot Urine Panel</p><p>(Albumin preferred) is recommended by guidelines, at least</p><p>yearly;</p><p>BONE and MINERAL ASSESSMENT</p><p>Carbon Dioxide is within goal and has risen, was 23 and now</p><p>is 26 mmol/L. Guidelines recommend the measurement of</p><p>25-hydroxy vitamin D in patients with CKD.</p><p>BONE and MINERAL TREATMENT SUGGESTIONS</p><p>-</p><p>Interpretations require simultaneous measurements of serum</p><p>calcium and phosphorus.</p><p>BONE and MINERAL FOLLOW-UP</p><p>-</p><p>fasting PTH with Renal Panel is recommended by guidelines,</p><p>at least yearly; 25-Hydroxy Vitamin D is due;</p><p>LIPIDS ASSESSMENT</p><p>Most recent order does not include a fasting Lipid Panel.</p><p>LIPIDS FOLLOW-UP</p><p>-</p><p>fasting Lipid Panel [REDACTED];</p><p>ANEMIA ASSESSMENT</p><p>Hemoglobin is low and has not changed significantly, was</p><p>11.2 and now is 11.4 g/dL. Hemoglobin target assumes ESA is</p><p>not in use.</p><p>ANEMIA TREATMENT SUGGESTIONS</p><p>-</p><p>Iron deficiency is a common cause of anemia in CKD.</p><p>Recommend measurement of Ferritin and TSAT.</p><p>ANEMIA FOLLOW-UP</p><p>-</p><p>Fe/TIBC (TSAT) and Ferritin with CBC is due; CBC within 3</p><p>months;</p><p>-------------------------------</p><p>DISCLAIMER</p><p>These assessments and treatment suggestions are provided as</p><p>a convenience in support of the physician-patient</p><p>relationship and are not intended to replace the physician's</p><p>clinical judgment. They are derived from national guidelines</p><p>in addition to other evidence and expert opinion. The</p><p>clinician should consider this information within the</p><p>context of clinical opinion and the individual patient.</p><p>SEE GUIDANCE FOR CHRONIC KIDNEY DISEASE PROGRAM: Kidney</p><p>Disease Improving Global Outcomes (KDIGO) clinical practice</p><p>guidelines are at http://kdigo.org/home/guidelines/.</p><p>National Kidney Foundation Kidney Disease Outcomes Quality</p><p>Initiative (KDOQI (TM)), with its limitations and</p><p>disclaimers, are at www.kidney.org/professionals/KDOQI. This</p><p>program is intended for patients who have been diagnosed</p><p>with stages 3, 4, or pre-dialysis 5 CKD. It is not intended</p><p>for children, pregnant patients, or transplant patients.</p></td></tr><tr><td ID="result9_attr2">PDF</td><td>.</td><td/><td/></tr></tbody></table></div><h3><a name="id3" href="#toc">Reason For Referral</a></h3><div><table width="100%" border="1"><tbody><tr><th>Reason</th><td>Physical therapy</td></tr><tr><th>Diagnosis 1</th><td>Closed fracture of left hip, initial encounter (S72.002A)</td></tr><tr><th>Referral Organization</th><td>MCM Pembroke Pines</td></tr><tr><th>Referring Provider First Name</th><td>[REDACTED]</td></tr><tr><th>Referring Provider Last Name</th><td>[REDACTED]</td></tr><tr><th>Referring Provider Speciality</th><td>Physician</td></tr><tr><th>Referred Provider</th><td>Motion MSK, Broward</td></tr><tr><th>Referred Provider Specialty</th><td>Orthopedic Surgery</td></tr><tr><th>Clinical Notes</th><td>[REDACTED] [REDACTED] 01:37:45 PM &gt;Is Motion. Faxed.</td></tr><tr><th>Referral Priority</th><td>Routine</td></tr></tbody></table></div><h3><a name="id4" href="#toc">Medications</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Pantoprazole Sodium 40 MG</td><td ID="instruction1">1 tablet Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication2">Healthy Eyes -</td><td ID="instruction2">as directed Orally</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication3">Vitamin D3 50 MCG (2000 UT)</td><td ID="instruction3">2 tablets Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication4">Simvastatin 40 MG</td><td ID="instruction4">TAKE 1 TABLET BY MOUTH EVERY DAY for 90</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication5">Eliquis 2.5 MG</td><td ID="instruction5">as directed Orally twice a day</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id5" href="#toc">Immunizations</a></h3><div><table width="100%" border="1"><thead><tr><th>Vaccine</th><th>Route</th><th>Administration Date</th><th>Status</th><th>Comments</th></tr></thead><tbody><tr><td ID="immunization1">Influenza (whole)</td><td>IM Intramuscular</td><td>[REDACTED]</td><td>Administered</td><td/></tr><tr><td ID="immunization2">Influenza (whole)</td><td>ID  Intradermal</td><td>[REDACTED]</td><td>Administered</td><td/></tr><tr><td ID="immunization3">Influenza (whole)</td><td>IM Intramuscular</td><td>[REDACTED]</td><td>Administered</td><td/></tr><tr><td ID="immunization4">Moderna Covid-19 Vaccine 1st dose</td><td>Unknown</td><td>[REDACTED]</td><td>Administered</td><td ID="immunization4notes">  Immunization Given by from source eCW:: </td></tr><tr><td ID="immunization5">Moderna Covid-19 Vaccine 1st dose</td><td>Unknown</td><td>[REDACTED]</td><td>Administered</td><td ID="immunization5notes">  Immunization Given by from source eCW:: </td></tr></tbody></table></div><h3><a name="id6" href="#toc">Social History</a></h3><div><span class="content_span">Tobacco Use:</span><table width="100%" border="1"><thead><tr><th>Social History Observation</th><th>Description</th><th>Date</th></tr></thead><tbody><tr><td ID="smokingStatus1">Details (start date - stop date)</td><td>Never Smoker</td><td>NA - NA</td></tr></tbody></table><span class="content_span">Sex Assigned At Birth:</span><table width="100%" border="1"><thead><tr><th>Social History Observation</th><th>Description</th></tr></thead><tbody><tr><td ID="BirthSexInfo">Sex Assigned At Birth</td><td>Male</td></tr></tbody></table><span class="content_span">Household</span><table width="100%" border="1"><thead><tr><th>Question</th><th>Answer</th><th>Notes</th></tr></thead><tbody><tr><td>Marital status:</td><td>married</td><td/></tr></tbody></table><span class="content_span">Tobacco Use/Smoking</span><table ID="socialhistorynotes" width="100%" border="1"><thead><tr><th>Question</th><th>Answer</th><th>Notes</th></tr></thead><tbody><tr><td>Tobacco use:</td><td>nonsmoker</td><td/></tr></tbody></table><span class="content_span">Alcohol Screen (Audit-C)</span><table width="100%" border="1"><thead><tr><th>Question</th><th>Answer</th><th>Notes</th></tr></thead><tbody><tr><td>Did you have a drink containing alcohol in the past year?</td><td>No</td><td/></tr><tr><td>Points</td><td>0</td><td/></tr><tr><td>Interpretation</td><td>Negative</td><td/></tr></tbody></table></div><h3><a name="id7" href="#toc">Problems</a></h3><div><table width="100%" border="1"><thead><tr><th>Problem Type</th><th>SNOMED Code</th><th>ICD Code</th><th>Onset Dates</th><th>Problem Status</th><th>W/U Status</th><th>Risk</th><th>Notes</th></tr></thead><tbody><tr><td>Problem</td><td>238107002</td><td ID="Problem1">Mild protein-calorie malnutrition (E44.1)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems1notes">advised to increase caloric intake and monitor weight closely.</td></tr><tr><td>Problem</td><td>3972004</td><td ID="Problem2">Primary insomnia (F51.01)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems2notes">stopped zolpidem. on lifestyle changes and sleep hygiene.</td></tr><tr><td>Problem</td><td>Vitiligo (56727007)</td><td ID="Problem3">Vitiligo (L80)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems3notes">dermatology consult, was seen and given a topical ointment. Will follow up with them in about a month.</td></tr><tr><td>Problem</td><td>Atherosclerosis of aorta (81817003)</td><td ID="Problem4">Atherosclerosis of aorta (I70.0)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems4notes">Advised to decrease intake of high cholesterol food and exercise more often as tolerated. Recheck cholesterol level [REDACTED]. Currently on Statin. No Myalgia.</td></tr><tr><td>Problem</td><td>Chronic kidney disease stage 3A (disorder) (700378005)</td><td ID="Problem5">Chronic kidney disease, stage 3a (N18.31)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems5notes">Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td></tr><tr><td>Problem</td><td>428283002</td><td ID="Problem6">History of colon polyps (Z86.010)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems6notes">Has repeated Colonoscopy 10-23, that was unremarkable. No need to further repeat due to age.</td></tr><tr><td>Problem</td><td>428262008</td><td ID="Problem7">History of prostate cancer (Z85.46)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems7notes">Stable; Continue close monitoring</td></tr><tr><td>Problem</td><td>55822004</td><td ID="Problem8">Hyperlipidemia (E78.5)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems8notes">Repeat lipids. Low cholesterol diet. Continue on same Rx.</td></tr><tr><td>Problem</td><td>Vitamin D deficiency (34713006)</td><td ID="Problem9">Vitamin D deficiency (E55.9)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems9notes"><p>Will start with Vit D 50,000 once a week for 3 months. Re evaluate [REDACTED]</p><p>[REDACTED]: improved significantly to 86. Continue with OTC vitamin D.</p></td></tr><tr><td>Problem</td><td>70995007</td><td ID="Problem10">Pulmonary HTN (I27.20)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems10notes">stable. Educated about controlling HTN.. Asymptomatic.</td></tr><tr><td>Problem</td><td>231473004</td><td ID="Problem11">Benzodiazepine dependence (F13.20)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems11notes">on zolpidem for chronic insomnia. Unable to wean off (worsening insomnia). Educated about side effects of Zolpidem including addictiveness. Understands but helps him sleep better.</td></tr><tr><td>Problem</td><td>193003</td><td ID="Problem12">Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified (I12.9)</td><td/><td>Active</td><td>confirmed</td><td/><td ID="problems12notes">Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td></tr></tbody></table></div><h3><a name="id8" href="#toc">Vital Signs</a></h3><div><table width="100%" border="1"><tbody><tr><th ID="vital1">Heart Rate</th><td>106 /min</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital2">Respiratory Rate</th><td>16 /min</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital3">Blood pressure diastolic</th><td>63 mm Hg</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital4">Height-cm</th><td>167.64 cm</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital5">Weight-kg</th><td>51.71 kg</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital6">Height</th><td>5 ft 6 in in</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital7">Blood pressure systolic</th><td>112 mm Hg</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital8">Weight</th><td>114 lbs</td><td>[REDACTED]</td><td/></tr><tr><th ID="vital9">BMI</th><td>18.4 kg/m2</td><td>[REDACTED]</td><td/></tr></tbody></table></div><h3><a name="id9" href="#toc">Procedures</a></h3><div><table width="100%" border="1"><thead><tr><th>Procedure</th><th>Date Ordered</th><th>Date Performed</th><th>Result</th><th>Body Site</th></tr></thead><tbody><tr><td ID="procedure1">HEDIS: Blood Pressure Diastolic 80-89</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure2">HEDIS: Blood Pressure Systolic 130-139</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure3">HEDIS: COA Functional Status</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure4">HEDIS: COA Medication Review</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure5">HEDIS: COA Pain Not Present</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure6">HEDIS: Depression Screening (If completed)</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure7">HEDIS: Fall Risk (If completed)</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure8">HEDIS: Tobacco Non-User</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure9">HEDIS: Advanced Care Planning</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure10">HEDIS: BMI &lt; 22</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure11">HEDIS: Depression Screening - Negative</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr><tr><td ID="procedure12">HEDIS: Fall Risk - No Falls or 1 fall</td><td>[REDACTED]</td><td>[REDACTED]</td><td>N/A</td><td/></tr></tbody></table></div><h3><a name="id10" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Hyperlipidemia E78.5</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Primary insomnia F51.01</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td/></tr><tr><td>MCM [REDACTED]</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Hyperlipidemia E78.5</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td/></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Annual physical exam Z00.00 ; Hyperlipidemia E78.5 ; ANEMIA D64.9 ; Vitamin D deficiency E55.9 ; History of colon polyps Z86.010 ; Vitiligo L80 ; Pulmonary HTN I27.20 ; Chronic kidney disease, stage 3a N18.31 ; Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified I12.9 ; Primary insomnia F51.01 and Atherosclerosis of aorta I70.0</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Hyperlipidemia E78.5 ; ANEMIA D64.9 ; Vitamin D deficiency E55.9 ; History of colon polyps Z86.010 ; Vitiligo L80 ; Pulmonary HTN I27.20 ; Chronic kidney disease, stage 3a N18.31 ; Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified I12.9 ; Primary insomnia F51.01 ; Atherosclerosis of aorta I70.0 ; History of prostate cancer Z85.46 and Hyperglycemia R73.9</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Hyperlipidemia E78.5 ; ANEMIA D64.9 ; Vitamin D deficiency E55.9 ; History of colon polyps Z86.010 ; Vitiligo L80 ; Pulmonary HTN I27.20 ; Chronic kidney disease, stage 3a N18.31 ; Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified I12.9 and Primary insomnia F51.01</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Primary insomnia F51.01 and Benzodiazepine dependence F13.20</td></tr><tr><td>MCM Pembroke Pines</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Hyperlipidemia E78.5 ; Hospital discharge follow-up Z09 ; ANEMIA D64.9 ; Vitamin D deficiency E55.9 ; History of colon polyps Z86.010 ; Vitiligo L80 ; Pulmonary HTN I27.20 ; Chronic kidney disease, stage 3a N18.31 ; Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified I12.9 ; Primary insomnia F51.01 ; Atherosclerosis of aorta I70.0 ; History of prostate cancer Z85.46 ; Hyperglycemia R73.9 ; Closed displaced fracture of left acetabulum with routine healing, unspecified portion of acetabulum, subsequent encounter S32.402D ; Closed fracture of ramus of left pubis with routine healing, subsequent encounter S32.592D ; BMI less than [REDACTED],adult Z68.1 and Mild protein-calorie malnutrition E44.1</td></tr></tbody></table></div><h3><a name="id11" href="#toc">Medical Equipment</a></h3><div>No Information</div><h3><a name="id12" href="#toc">Assessments</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis (ICD Code)</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th></tr></thead><tbody><tr><td ID="ref1">[REDACTED]</td><td>Hyperlipidemia (ICD-10 - E78.5)</td><td>Repeat lipids. Low cholesterol diet. Continue on same Rx.</td><td/><td/></tr><tr><td ID="ref2">[REDACTED]</td><td>ANEMIA (ICD-10 - D64.9)</td><td>Hg=11.1, Hct=35.5. Ferritin, Vit B12/Folic Acid, and Reticulocytes=WNL. FOBT=not done (re order). Has appt with GI in October for repeat Colonoscopy with Dr. Baikovitz.</td><td/><td/></tr><tr><td ID="ref3">[REDACTED]</td><td>Hyperlipidemia (ICD-10 - E78.5)</td><td/><td/><td/></tr><tr><td ID="ref4">[REDACTED]</td><td>Hyperlipidemia (ICD-10 - E78.5)</td><td>Repeat lipids. Low cholesterol diet. Continue on same Rx.</td><td/><td/></tr><tr><td ID="ref5">[REDACTED]</td><td>Annual physical exam (ICD-10 - Z00.00)</td><td/><td/><td/></tr><tr><td ID="ref6">[REDACTED]</td><td>Primary insomnia (ICD-10 - F51.01)</td><td>zolpidem 5mg qhs prn</td><td/><td/></tr><tr><td ID="ref7">[REDACTED]</td><td>Primary insomnia (ICD-10 - F51.01)</td><td>zolpidem 5mg qhs prn refilled. EFORCE checked prior to Rx.</td><td/><td/></tr><tr><td ID="ref8">[REDACTED]</td><td>Benzodiazepine dependence (ICD-10 - F13.20)</td><td>on zolpidem for chronic insomnia. Unable to wean off (worsening insomnia). Educated about side effects of Zolpidem including addictiveness. Understands but helps him sleep better.</td><td/><td/></tr><tr><td ID="ref9">[REDACTED]</td><td>Hyperlipidemia (ICD-10 - E78.5)</td><td>Repeat lipids. Low cholesterol diet. Continue on same Rx.</td><td/><td/></tr><tr><td ID="ref10">[REDACTED]</td><td>ANEMIA (ICD-10 - D64.9)</td><td>Ferritin, Vit B12/Folic Acid, and Reticulocytes=WNL. FOBT=not done (re order). Has appt with GI in October for repeat Colonoscopy with Dr. Baikovitz.</td><td/><td/></tr><tr><td ID="ref11">[REDACTED]</td><td>Hyperlipidemia (ICD-10 - E78.5)</td><td/><td/><td/></tr><tr><td ID="ref12">[REDACTED]</td><td>Hyperlipidemia (ICD-10 - E78.5)</td><td>Repeat lipids. Low cholesterol diet. Continue on same Rx.</td><td/><td/></tr><tr><td ID="ref13">[REDACTED]</td><td>Hospital discharge follow-up (ICD-10 - Z09)</td><td>stable. agree with current managemen. Meds reconciled.</td><td/><td/></tr><tr><td ID="ref14">[REDACTED]</td><td>ANEMIA (ICD-10 - D64.9)</td><td>no bleeding. Stable. recheck H/H</td><td/><td/></tr><tr><td ID="ref15">[REDACTED]</td><td>Vitamin D deficiency (ICD-10 - E55.9)</td><td><p>Will start with Vit D 50,000 once a week for 3 months. Re evaluate [REDACTED]</p><p>[REDACTED]: improved significantly to 86. Continue with OTC vitamin D.</p></td><td/><td/></tr><tr><td ID="ref16">[REDACTED]</td><td>ANEMIA (ICD-10 - D64.9)</td><td> Ferritin, Vit B12/Folic Acid, and Reticulocytes=WNL. FOBT=not done (re order). Has appt with GI in October for repeat Colonoscopy with Dr. Baikovitz.</td><td/><td/></tr><tr><td ID="ref17">[REDACTED]</td><td>Vitamin D deficiency (ICD-10 - E55.9)</td><td><p>Will start with Vit D 50,000 once a week for 3 months. Re evaluate [REDACTED]</p><p>[REDACTED]: improved significantly to 86. Continue with OTC vitamin D.</p></td><td/><td/></tr><tr><td ID="ref18">[REDACTED]</td><td>Vitamin D deficiency (ICD-10 - E55.9)</td><td><p>Will start with Vit D 50,000 once a week for 3 months. Re evaluate [REDACTED]</p><p>[REDACTED]: improved significantly to 86. Continue with OTC vitamin D.</p></td><td/><td/></tr><tr><td ID="ref19">[REDACTED]</td><td>History of colon polyps (ICD-10 - Z86.010)</td><td>Has repeated Colonoscopy that was unremarkable. No need to further repeat due to age.</td><td/><td/></tr><tr><td ID="ref20">[REDACTED]</td><td>History of colon polyps (ICD-10 - Z86.010)</td><td>Has repeated Colonoscopy 10-23, that was unremarkable. No need to further repeat due to age.</td><td/><td/></tr><tr><td ID="ref21">[REDACTED]</td><td>Vitamin D deficiency (ICD-10 - E55.9)</td><td><p>Will start with Vit D 50,000 once a week for 3 months. Re evaluate [REDACTED]</p><p>[REDACTED]: improved significantly to 86. Continue with OTC vitamin D.</p></td><td/><td/></tr><tr><td ID="ref22">[REDACTED]</td><td>History of colon polyps (ICD-10 - Z86.010)</td><td>Has repeated Colonoscopy 10-23, that was unremarkable. No need to further repeat due to age.</td><td/><td/></tr><tr><td ID="ref23">[REDACTED]</td><td>History of colon polyps (ICD-10 - Z86.010)</td><td>Has repeated Colonoscopy 10-23, that was unremarkable. No need to further repeat due to age.</td><td/><td/></tr><tr><td ID="ref24">[REDACTED]</td><td>Vitiligo (ICD-10 - L80)</td><td>dermatology consult, was seen and given a topical ointment. Will follow up with them in about a month.</td><td/><td/></tr><tr><td ID="ref25">[REDACTED]</td><td>Vitiligo (ICD-10 - L80)</td><td>dermatology consult, was seen and given a topical ointment. Will follow up with them in about a month.</td><td/><td/></tr><tr><td ID="ref26">[REDACTED]</td><td>Pulmonary HTN (ICD-10 - I27.20)</td><td>stable. Educated about controlling HTN.. Asymptomatic.</td><td/><td/></tr><tr><td ID="ref27">[REDACTED]</td><td>Vitiligo (ICD-10 - L80)</td><td>dermatology consult, was seen and given a topical ointment. Will follow up with them in about a month.</td><td/><td/></tr><tr><td ID="ref28">[REDACTED]</td><td>Pulmonary HTN (ICD-10 - I27.20)</td><td>stable. Educated about controlling HTN.. Asymptomatic.</td><td/><td/></tr><tr><td ID="ref29">[REDACTED]</td><td>Vitiligo (ICD-10 - L80)</td><td>dermatology consult, was seen and given a topical ointment. Will follow up with them in about a month.</td><td/><td/></tr><tr><td ID="ref30">[REDACTED]</td><td>Pulmonary HTN (ICD-10 - I27.20)</td><td>stable. Educated about controlling HTN.. Asymptomatic.</td><td/><td/></tr><tr><td ID="ref31">[REDACTED]</td><td>Chronic kidney disease, stage 3a (ICD-10 - N18.31)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref32">[REDACTED]</td><td>Pulmonary HTN (ICD-10 - I27.20)</td><td>stable. Educated about controlling HTN.. Asymptomatic.</td><td/><td/></tr><tr><td ID="ref33">[REDACTED]</td><td>Chronic kidney disease, stage 3a (ICD-10 - N18.31)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref34">[REDACTED]</td><td>Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified (ICD-10 - I12.9)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref35">[REDACTED]</td><td>Chronic kidney disease, stage 3a (ICD-10 - N18.31)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref36">[REDACTED]</td><td>Chronic kidney disease, stage 3a (ICD-10 - N18.31)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref37">[REDACTED]</td><td>Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified (ICD-10 - I12.9)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref38">[REDACTED]</td><td>Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified (ICD-10 - I12.9)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref39">[REDACTED]</td><td>Benign hypertensive kidney disease with chronic kidney disease stage I through stage IV, or unspecified (ICD-10 - I12.9)</td><td>Pathophysiology of the diagnosis discussed, including measures to minimize progression of the disease like avoiding NSAIDS and other nephrotoxic meds. Diet: 2g sodium, 2g potassium, 60g protein. Control HTN.</td><td/><td/></tr><tr><td ID="ref40">[REDACTED]</td><td>Primary insomnia (ICD-10 - F51.01)</td><td>stopped zolpidem. on lifestyle changes and sleep hygiene.</td><td/><td/></tr><tr><td ID="ref41">[REDACTED]</td><td>Primary insomnia (ICD-10 - F51.01)</td><td>zolpidem 5mg qhs prn</td><td/><td/></tr><tr><td ID="ref42">[REDACTED]</td><td>Atherosclerosis of aorta (ICD-10 - I70.0)</td><td>Advised to decrease intake of high cholesterol food and exercise more often as tolerated. Recheck cholesterol level [REDACTED]. Currently on Statin. No Myalgia.</td><td/><td/></tr><tr><td ID="ref43">[REDACTED]</td><td>Primary insomnia (ICD-10 - F51.01)</td><td>stopped zolpidem. on lifestyle changes and sleep hygiene.</td><td/><td/></tr><tr><td ID="ref44">[REDACTED]</td><td>Primary insomnia (ICD-10 - F51.01)</td><td>stopped zolpidem. on lifestyle changes and sleep hygiene.</td><td/><td/></tr><tr><td ID="ref45">[REDACTED]</td><td>Atherosclerosis of aorta (ICD-10 - I70.0)</td><td>Advised to decrease intake of high cholesterol food and exercise more often as tolerated. Recheck cholesterol level [REDACTED]. Currently on Statin. No Myalgia.</td><td/><td/></tr><tr><td ID="ref46">[REDACTED]</td><td>Atherosclerosis of aorta (ICD-10 - I70.0)</td><td>Advised to decrease intake of high cholesterol food and exercise more often as tolerated. Recheck cholesterol level [REDACTED]. Currently on Statin. No Myalgia.</td><td/><td/></tr><tr><td ID="ref47">[REDACTED]</td><td>History of prostate cancer (ICD-10 - Z85.46)</td><td>Stable; Continue close monitoring</td><td/><td/></tr><tr><td ID="ref48">[REDACTED]</td><td>Hyperglycemia (ICD-10 - R73.9)</td><td>monitor glucose closely. low carbs diet encouraged.</td><td/><td/></tr><tr><td ID="ref49">[REDACTED]</td><td>History of prostate cancer (ICD-10 - Z85.46)</td><td>Stable; Continue close monitoring</td><td/><td/></tr><tr><td ID="ref50">[REDACTED]</td><td>Hyperglycemia (ICD-10 - R73.9)</td><td>monitor glucose closely. low carbs diet encouraged.</td><td/><td/></tr><tr><td ID="ref51">[REDACTED]</td><td>Closed displaced fracture of left acetabulum with routine healing, unspecified portion of acetabulum, subsequent encounter (ICD-10 - S32.402D)</td><td>stable. Fu with Ortho and Physical Therapy.</td><td/><td/></tr><tr><td ID="ref52">[REDACTED]</td><td>Closed fracture of ramus of left pubis with routine healing, subsequent encounter (ICD-10 - S32.592D)</td><td>stable. Fu with Ortho and Physical Therapy.</td><td/><td/></tr><tr><td ID="ref53">[REDACTED]</td><td>BMI less than 19,adult (ICD-10 - Z68.1)</td><td>advised to increase caloric intake and monitor weight closely.</td><td/><td/></tr><tr><td ID="ref54">[REDACTED]</td><td>Mild protein-calorie malnutrition (ICD-10 - E44.1)</td><td>advised to increase caloric intake and monitor weight closely.</td><td/><td/></tr></tbody></table></div><h3><a name="id13" href="#toc">Plan Of Treatment</a></h3><div><span class="content_span">Pending Test</span><table width="100%" border="1"><thead><tr><th>Test Name</th><th>Order Date</th></tr></thead><tbody><tr><td ID="pendingTest1">Urinalysis, Complete</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest2">CBC With Differential/Platelet</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest3">Lipid Panel, Fasting</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest4">Comp. Metabolic Panel (14), Fasting</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest5">POTASSIUM (733)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest6">PSA (FREE AND TOTAL) (31348)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest7">T4 (THYROXINE), TOTAL (867)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest8">T4 (THYROXINE), TOTAL (867)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest9">TSH (899)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest10">TSH (899)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest11">FECAL GLOBIN BY IMMUNOCHEMISTRY</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest12">LIPID PANEL WITH REFLEX TO DIRECT LDL</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest13">VITAMIN D, 25-HYDROXY, LC/MS/MS</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest14">HEMOGLOBINOPATHY EVALUATION</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest15">PSA Total (Reflex To Free)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest16">CBC With Differential/Platelet</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest17">CBC With Differential/Platelet</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest18">Occult Blood, Fecal, IA</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest19">Lipid Panel</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest20">Comp. Metabolic Panel (14)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest21">Urinalysis, Complete</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest22">ANTINUCLEAR ANTIBODIES   TITER AND PATTERN</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest23">Echocardiogram</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest24">X ray : LS Spine</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest25">EKG</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest26">EKG</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest27">Echocardiogram</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest28">Echocardiogram</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest29">HEDIS: Depression Screening (If completed)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest30">HEDIS: Fall Risk (If completed)</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest31">HEDIS: Tobacco Non-User</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest32">HEDIS: BMI 22 - 30</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest33">HEDIS: Depression Screening - Negative</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest34">HEDIS: Fall Risk - No Falls or 1 fall</td><td>[REDACTED]</td></tr></tbody></table><span class="content_span">Future Test</span><table width="100%" border="1"><thead><tr><th>Test Name</th><th>Order Date</th></tr></thead><tbody><tr><td ID="futureTest1">CBC With Differential/Platelet-005009</td><td>[REDACTED]</td></tr><tr><td ID="futureTest2">Comp. Metabolic Panel (14)-322000</td><td>[REDACTED]</td></tr></tbody></table><span class="content_span">Next Appt</span><table width="100%" border="1"><thead><tr><th>Details</th></tr></thead><tbody><tr><td ID="futureAppt1">Provider Name:[REDACTED], [REDACTED] 10:00:00 AM, [REDACTED][REDACTED], [REDACTED]</td></tr><tr><td ID="futureAppt2">Provider Name:[REDACTED], [REDACTED] 02:00:00 PM, [REDACTED][REDACTED], [REDACTED]</td></tr></tbody></table></div><h3><a name="id14" href="#toc">Goals Section</a></h3><div>No Information</div><h3><a name="id15" href="#toc">Health Concerns</a></h3><div>No Information</div><h3><a name="id16" href="#toc">Insurance Providers</a></h3><div><table width="100%" border="1"><thead><tr><th>Payer Name</th><th>Payer Address</th><th>Payer Phone</th><th>Subscriber Number</th><th>Group Number</th><th>Insured Name</th><th>Patient Relationship to Insured</th><th>Coverage Start Date</th><th>Coverage End Date</th></tr></thead><tbody><tr><td>Careplus MCR</td><td>PO BOX 31286 [REDACTED], [REDACTED] 33631-3320</td><td>[REDACTED]</td><td>115576401</td><td/><td>Phadungpund, Thavorn</td><td>Self - patient is the insured</td><td/><td/></tr></tbody></table></div><h3><a name="id17" href="#toc">Medical (General) History</a></h3><div><span class="content_span">Medical History</span><table width="100%" border="1"><thead><tr><th>History</th><th>ICD Code</th></tr></thead><tbody><tr><td>HYPERLIPIDEMIA</td><td/></tr><tr><td>BENIGN PROSTATE HYPERPLASIA</td><td/></tr><tr><td>Nonspecific abnormal finding in stool contents</td><td/></tr><tr><td>Prostate cancer</td><td/></tr></tbody></table><span class="content_span">Hospitalization History</span><table width="100%" border="1"><thead><tr><th>Reason</th><th>Date(Month/Year)</th></tr></thead><tbody><tr><td>PROSTATITIS</td><td>2005</td></tr><tr><td>KIDNEY INFECTION</td><td>1998</td></tr></tbody></table></div><br/><br/>
</body></html>